ArticleEuropean geriatric medicine2025
Fndc5/irisin mediates the benefits of aerobic exercise intervention on aging-associated sarcopenia in mice.
Article in European geriatric medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Protective effects of irisin in sarcopenia: a promising treatment.Journal of orthopaedic translation · 2026Review
- Integrin αVβ5 regulates myoblast proliferation and differentiation in sarcopenia mice treated with FNDC5 gene delivery : Original article.Skeletal muscle · 2026Article
- Thermogenic adipose tissue in older adults with obesity: a narrative review of mechanisms, brown fat resistance, and the translational relevance of exercise and nutrition.Frontiers in nutrition · 2026Review
- Neural Cues and Genomic Clues: NGS Insights into Neurogenic Sarcopenia and Muscle Atrophy.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
methodsIn this study, 24-month-old (aged) mice were used as a naturally occurring model of aging-associated sarcopenia, while 2-month-old (young) mice served as the normal control. Six weeks of treadmill training was employed as an aerobic exercise intervention. The mRNA and protein levels of fibronectin type III domain-containing protein 5 (Fndc5/irisin), MuRF1, and Atrogin-1 in gastrocnemius muscles were analyzed using qRT-PCR and Western blot. Oxidative stress was assessed using relevant detection kits. Skeletal muscle function was evaluated through the four-paw hanging test, rotarod test, grip strength assay, and measurements of quadriceps, tibialis anterior, and gastrocnemius muscle mass.
resultsAerobic exercise interventions enhanced skeletal muscle function by increasing hanging time, maximum speed, grip strength, and increased quadriceps, gastrocnemius, and tibialis anterior muscle mass. On the other hand, aerobic exercise reduced MuRF1 and Atrogin-1 expression in the gastrocnemius muscles of sarcopenia mice, along with lower malondialdehyde levels, and higher superoxide dismutase activity, T-ATPase, and glutathione peroxidase activity. A decline in Fndc5/irisin expression was further detected in the gastrocnemius muscles with aging. In Fndc5-knockout aged mice, aerobic exercise failed to improve skeletal muscle function compared to wild-type aged mice, as evaluated by hanging time, grip strength, maximum speed, and quadriceps, gastrocnemius, and tibialis anterior muscle mass, further validating the involvement of Fndc5 in the improvement of aging-associated sarcopenia.
conclusionAerobic exercise improves aging-associated sarcopenia in mice, with Fndc5/irisin playing a role in this process.
Indexed as
Identifiers
40080339What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.